Clinical Study

Vb-111-70/Gog-3018- A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study Of Ofranergene Obadenovec (Vb-111) Combined With Paclitaxel Vs. Paclitaxel Combined With Placebo For The Treatment Of Recurrent Platinum-Resistant Ovarian Cancer

Posted Date: Oct 15, 2019

  • Investigator: Thomas Herzog
  • Specialties: Cancer, Ovarian Cancer
  • Type of Study: Drug

The goal of this study is to evaluate the safety, tolerability, and efficacy of the combination of intravenous administration of VB-111 and paclitaxel compared to placebo and paclitaxel in patients with platinum resistant ovarian cancer as measured by overall survival (OS).

Criteria:

To Be Eligible: 18 Yrs Of Age Or Older, Female, Diagnosed With Epithelial Ovarian Cancer, Life Expectency >/= 12 Weeks, Nonpregnant/Nonbreastfeeding, No Prior Radiotherapy To Pelvis Or Abdomen, No Other Uncontrolled Active Infection Or Illness

Keywords:

Ovarian Cancer

For More Information:

Ucci Cancer Institute
513-584-7698
cancer@uchealth.com


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.